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Purpose: The aim of the present study was to evaluate the effectiveness of the ultramicro-
nized-palmitoylethanolamide (um-PEA) and co-micronised palmitoylethanolamide/polydatin
m(PEA/PLD) in the management of chronic pelvic pain related to endometriosis in patients
desiring pregnancy.
Patients and methods: Thirty symptomatic women with laparoscopic diagnosis of endome-
triosis and pregnancy desire were enrolled. Patients were treated with um-PEA twice daily for 10
days followed by m(PEA/PLD) twice daily for 80 days. Intensity of chronic pelvic pain,
dyspareunia, dysmenorrhea, dyschezia, and dysuria were evaluated at baseline, after 10, 30,
60, 90 days and after 30 days from the end of treatment, by VAS. Quality of life and women’s
psychological well-being were evaluated at baseline and at the end of the treatment after 90 days
with 36-Item Short Form Health Survey questionnaire and Symptom Check list-90 question-
naire, respectively. All collected data were analyzed with the non-parametric Wilcoxon test.
Results: At the end of the treatment, all patients showed a signiﬁcant improvement in
chronic pelvic pain, deep dyspareunia, dysmenorrhea, dyschezia, as well as in quality of life
and psychological well-being.
Conclusion: In spite of the study’s limited sample size and the open-label design, this
research suggests the efﬁcacy of um-PEA and m(PEA/PLD) in reducing painful symptoma-
tology and improving quality of life as well as psychological well-being in patients suffering
from endometriosis. Additionally, this treatment did not show any serious side effect, proving
particularly suitable for women with pregnancy desire and without other infertility factors.
Keywords: endometriosis, chronic pelvic pain, psychological well-being, quality of life,
ultramicronized-palmitoylethanolamide, co-micronized palmitoylethanolamide and polydatin
Introduction
Endometriosis is an estrogen-dependent chronic benign inﬂammatory disease character-
ized by the presence and growth of endometrial tissue outside uterine cavity, most
commonly in pelvic organs and peritoneum and in some rare cases in extra-abdominal
locations.1,2 The presence of ectopic endometrium associated with cellular activity in the
lesions and progression leads to formation of adhesions and/or interference with the
normal reproductive processes.3 The etiology of the disease is not clearly deﬁned and is
probably multifactorial.4 Endometriosis affects approximately 10–20% of women in the
reproductive age, causing pain and infertility.5Moreover, this chronic disease importantly
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affects the quality of life as well as sexual and psychological
health.6,7 Severe and chronic pain causes functional disability
and requires medical/surgical treatment.8,9 For many years,
surgical treatment was considered the best approach due to its
effectiveness on symptoms and lesion eradications.10
Unfortunately, recent data indicate a high recurrence rate
after surgery and possible complications related to extensive
surgery especially on the ovarian reserve.11 Current treatments
are aimed primarily at resolving symptoms in a non-invasive
and palliative way. Hormonal therapies are considered the
primary choice. These drugs achieve an acyclic, hypo-estro-
genic environment avoiding ovarian estrogen production
(GnRH agonists and antagonists), inducing pseudo-pregnancy,
or locally inhibiting ectopic endometrium estrogenic stimula-
tion (progestins).12,13
In recent years, considerable experimental and clinical
evidence has emerged to support the involvement of mast
cells in pain associated with endometriosis.14,15 Increased
numbers of activated mast cells have been found in endome-
triotic lesions and in particular in deep inﬁltrating lesions
(typically associated with more severe pelvic pain), proximal
to nerves, suggesting that mast cells may contribute to endo-
metriotic pain by a direct effect on nerve structures.16,17 In
fact, mast cells dysregulation may cause an excessive release
of pro-inﬂammatory products responsible of peripheral neu-
ronal sensitization processes which are ampliﬁed by micro-
glial activation at the central level, with the development of
chronic pelvic pain.18,19 Moreover, cytokines and growth
factors secreted appear to promote invasion and growth of
ectopic endometrium by inducing proliferation and
angiogenesis.20 Therefore, mast cells may be an innovative
target for therapeutic strategies designed to reduce both
inﬂammation and the consequent hyperalgesia and allodynia
in endometriosis patients.21
Among the molecules acting on immune inﬂammatory
cells, palmitoylethanolamide (PEA) is of particular inter-
est. PEA is an endogenous fatty acid amide belonging to
the family of fatty acid ethanolamides, which plays a role
in the resolution of inﬂammatory processes by down-mod-
ulating mast cell activation and by controlling microglia
behavior.22,23 Another important element in the pathophy-
siology of endometriosis is oxidative stress, probably
involved in the growth and adhesion of endometrial cells
in the peritoneal cavity and consequent onset of the
disease.24 Polydatin (PLD), a glycoside of resveratrol, is
a molecule with well-known antioxidant and anti-chemo-
tactic activities, often combined with PEA in a co-micro-
nized form for the treatment of pain associated with
endometriosis.25,26 Micronization and ultra-micronization
of PEA produce a crystalline structure with higher energy
content and lower particle size, which contributes to better
distribution and diffusion than the naïve form.27,28
Pre-clinical studies have shown that ultra-micronized
PEA (um-PEA) by itself and PEA co-micronized with
polydatin m(PEA/PLD) signiﬁcantly reduce behavioral
indices of both uterine and ureteral pain and decrease
cyst formation.29,30 Importantly, m(PEA/PLD) markedly
reduced chronic pelvic pain associated with endometriosis
in woman either by itself or in combination with hormonal
or anti-inﬂammatory drugs.26,31–34
The aim of our study was to investigate whether um-
PEA followed by m(PEA/PLD) treatment in symptomatic
patients with laparoscopic diagnosis of endometriosis
improves symptoms and quality of life in these patients.
Materials and methods
This interventional study was conducted based on a
single-arm, non-randomized, open-label design.
Symptomatic women with laparoscopic diagnosis of
endometriosis were enrolled at the Department of the
Obstetrics and Gynecology, University of Cagliari, Italy,
between October 2013 and August 2015. Inclusion cri-
teria were: age between 18 and 48 years, diagnosis of
endometriosis on the base of laparoscopic and histolo-
gical examinations in last 3 years, chronic pain score ≥4
and ≤8 measured with the VAS, non-assumption of any
drug in the month before enrollment (in particular estro-
progestins, progestins, GnRH agonists, and antagonists),
persistence of symptoms for at least 1 month. The
exclusion criteria were: presence of other associated
diseases, assumption of drugs, menopause, pregnancy,
adverse reaction, or hyper sensitivity to active substance
or excipients, unavailability to sign informed consent.
This study was performed in accordance with the Good
Clinical Practice guidelines and the principles of the
Declaration of Helsinki of 1964 and its subsequent
revisions; it was approved by our institutional ethics
committee and registered in the clinicaltrial.gov website
at the Number NCT02372903.
After written informed consents were provided, um-
PEA 600 mg (Normast 600; Epitech Group, Italy) micro
granules were administered twice daily for 10 days fol-
lowed by m(PEA/PLD) (400 mg+40 mg) (Pelvilen Forte,
Epitech Group, Italy) micro granules, twice daily for 80
days. The drugs were taken orally 12 hrs apart, not neces-
sarily related to meals.
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In all patients, a trans-vaginal ultrasound exam and
cancer antigen 125 (CA 125) were performed to rule out
other possible causes of gynecological pain, unrelated to
endometriosis.
The main outcomes were the effect of the treatment on:
1) Intensity of pain, dyspareunia, dysmenorrhea, dys-
chezia, and dysuria evaluated with VAS. VAS is repre-
sented by a line 10 cm long with one extremity (0)
indicating no pain and the other (10) the worst pain
imaginable;35
2) Quality of life evaluated with the 36-Item Short Form
Health Survey questionnaire (SF-36). The SF-36 consist of
36 items which tap eight different health concepts such as
physical functioning, body pain, role limitations due to phy-
sical health problems, role limitations due to personal or
emotional problems, emotional well-being, social function-
ing, energy/fatigue, and general health perceptions. Score
calculation consists of two steps. First, the pre-coded numer-
ical values assigned to each question are recoded in a score
from 0 to 100 according to a pre-established scoring key. In
step 2, Items belonging to the same scale are averaged
together to create the 8 scale scores. A high scale score
indicates a more favorable health state;36,37
3) Psychological well-being was evaluated with
Symptom Check list-90 (SCL-90). SCL-90 is a self-report
measurement scale of 90 questions covering a wide range
of psycho-pathological symptoms such as somatization,
obsessive-compulsive syndrome, interpersonal sensitivity,
depression, anxiety, hostility, phobic anxiety, paranoid
ideation, psychoticism, and sleep disorders. Each item of
the questionnaire is scored from 0 (not at all) to 4 (extre-
mely) (Likert scale). All items with symptoms (score≥1)
are counted indicating the “Positive Symptoms Total”. A
high scale score deﬁnes a more psycho-pathologic state.38
VAS was administered at baseline, after 10, 30, 60 and
90 days and 30 days after the end of treatment (120 days),
while SF-36 and SCL-90 were administered at baseline
and at the end of treatment after 90 days.
Analgesic use was strictly monitored. Ketoprofen lysine
salt sachet 80 mg was the FANS drug allowed for a max-
imum of twice a day. Patients were invited to collect data in a
diary provided to them about every analgesic assumption and
even about any side effect of the treatment.
Statistical analysis
Data were analyzed using the statistical software package
IBM SPSS Statistics Desktop 22.0. The Kolmogorov–
Smirnov test was used to evaluate whether values had a
Gaussian distribution, in order to choose between para-
metric and non-parametric statistical tests. They were sum-
marized as the mean and SD for continuous data and as the
frequency for categorical data. Within-group variations
between baseline and follow-up-values were evaluated
using Wilcoxon matched pairs test. Signiﬁcance level
was accepted at p<0.05.
Results
Thirty symptomatic women with laparoscopic diagnosis of
endometriosis were enrolled. Only two patients withdrew
from the study, one due to pelvic inﬂammatory disease
and, the other for non-compliance with therapy.
Statistical analysis showed that all pain symptoms
decreased between baseline and 90 days (end of treat-
ment). In particular, the VAS mean score of chronic pelvic
pain signiﬁcantly decreased (p<0.0001) from 7.2±1.2 (CI
6.0–8.4) to 2.6±0.4 (CI 2.2–3) (p<0.05); further, dysme-
norrhea, dyspareunia, and dyschezia mean scores signiﬁ-
cantly decreased from 7.7±1.1 (CI 6.6–8.8) to 5.5±0.5 (CI
5–6) (p<0.05), from 4.9±1.3 (CI 3.6–6.2) to 1.9±0.4
(CI1.5–2.3) (p<0.05), and from 3.6±0.9 (CI 2.7–4.5) to
1.8±0.3 (CI 1.5–2.1) (p<0.05), respectively. Dysuria
mean score showed a reduction trend from 2.5±0.7 (CI
1.8–3.2) to 1.6±0.5 (CI 1.1–2.1) (n.s). Thirty days after the
end of treatment, VAS mean scores of all evaluated vari-
ables slightly increased; however, chronic pelvic pain and
dysmenorrhea mean scores maintained a statistically sig-
niﬁcant difference compared to baseline, moving to 4.2
±0.3 (CI 3.9–3.9) (p<0.05) and to 6.7±0.7 (CI 6–7.4)
(p<0.05), respectively. All the VAS mean scores at each
time point are presented in Figure 1. Obviously, the 10-day
follow-up for menstrual and sexual pain was analyzed only
in the patients who had periods or intercourse.
At the end of treatment, average values from self-
administered questionnaires were indicative of a positive
change in the quality of life and psychological well-being:
the score of all SF-36 questionnaire subscale as well as the
Positive Symptoms Total of the SCL-90 signiﬁcantly
improved (p<0.0005) (Tables 1, 2). The general improve-
ment on the variables considered was accompanied by a
signiﬁcant reduction in the use of the analgesic ketoprofen
at the end of the treatment (Figure 2). Treatment was well
tolerated and adverse events were not observed.
Discussion
Endometriosis is increasingly being recognized as an
inﬂammatory condition, where the increased presence of
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activated and degranulating mast cells, in particular in
inﬁltrating lesions, proximal to nerves, play a role in the
development of chronic pelvic pain.
The present study shows that treatment with um-PEA
followed by m(PEA/PLD) in patients affected from
symptomatic endometriosis leads to a signiﬁcant reduction
in the intensity of painful symptoms and improvement in
quality of life and psychological well-being.
These results conﬁrm the efﬁcacy of um-PEA and m
(PEA/PLD) for the management of chronic pelvic pain in
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Figure 1 Pain symptom scores obtained for the VAS at baseline, after 10, 30, 60, 90 days and after 30 days from the end of the treatment with um-PEA followed by m(PEA/
PLD) in patients affected from endometriosis. Intensity of chronic pelvic pain, dysmenorrhea, dyspareunia, and dyschezia showed a signiﬁcant reduction at each time point
compared to baseline. Thirty days after the end of the treatment, only chronic pelvic pain and dysmenorrhea mean score maintained a statistically signiﬁcant difference
compared to baseline. Data values are expressed as means±SD *A p-value of <0.05 was considered signiﬁcant.
Table 1 SF-36 subscale score at baseline and after 90 days of treatment with um-PEA followed by m(PEA/PLD) in patients suffering
from chronic pelvic pain due to endometriosis
SF-36 Baseline 90 days of treatment p-Value
Physical functioning 67±26 88±14 <0.0005
Role limitations as a result of physical problems 36±26 76±35 <0.0005
Bodily pain 54±21 72±20 <0.0005
General health perception 59±20 73±20 <0.0005
Vitality 46±18 65±15 <0.0005
Social functioning 61±26 83±20 <0.0005
Role limitations resulting from emotional problems 45±36 75±32 <0.0005
General mental health 53±17 60±15 <0.0005
Note: Data values are expressed as means±SD.
Abbreviations: SF-36, 36-Item Short Form Health Survey questionnaire; um-PEA, ultramicronized-palmitoylethanolamide; m(PEA/PLD), co-micronized palmitoylethano-
lamide/polydatin;.
Table 2 SCL-90 score (Positive Symptoms Total) at baseline and after 90 days of treatment with um-PEA followed by m(PEA/PLD) in
patients suffering from chronic pelvic pain due to endometriosis
SCL-90 Baseline 90 days of treatment p-Value
Positive Symptoms Total 75±8 37±6 p<0.001
Notes: Data values are expressed as means±SD A p-value of <0.05 was considered signiﬁcant.
Abbreviations: SCL-90, Symptom Check list-90 questionnaire; um-PEA, ultramicronized-palmitoylethanolamide; m(PEA/PLD), co-micronized palmitoylethanolamide/polydatin;.
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endometriosis. Past clinical studies have shown that both
um-PEA and m-PEA reduce chronic pain in patients suf-
fering from various pathological conditions including pel-
vic pain in the bladder pain syndrome, menstrual pain in
adolescents, and in particular in endometriosis.31,32,33,39,40
Cobellis et al in a double-blind study with three arms
showed that the beneﬁcial effects of m(PEA/PLD) are
comparable to those obtained with anti-inﬂammatory
drugs and more effective than placebos.32 Di Francesco
and Pizzigallo in an open-label controlled study obtained
signiﬁcant reduction in pelvic pain with m(PEA/PLD) as
well as with hormonal drugs (leuprorelin acetate or ethi-
nylestradiol+drospirenone), irrespective of the treatment
administered.33
PEA is an important anti-inﬂammatory drug with pain-
relieving properties, mainly involved in the downregula-
tion of mast cell activity.22 Further evidence support the
hypothesis that PEA can act directly, stimulating either an
as-yet uncharacterized cannabinoid CB2-like receptor, or
the nuclear receptor peroxisome proliferator-activated
receptor-alpha; moreover, it has been proposed that PEA
acts indirectly through an “entourage effect”, ie, enhancing
the anti-inﬂammatory and anti-nociceptive effects exerted
by anandamide.41
Apart from the characteristic symptomatic picture,
women with endometriosis present mood disorders (viz.,
depression and anxiety) and overall poor quality of life.8,9
In the present study, we were able to show that um-PEA
and m(PEA/PLD) treatment led to a signiﬁcant improvement
in patients’ global quality of life evaluated by the SF-36
questionnaire and in particular of all its scale scores related
to physical functioning, body pain, role limitations due to
physical health problems, role limitations due to personal or
emotional problems, emotional well-being, social function-
ing, energy/fatigue, and general health perceptions. Similar
results were obtained by Di Francesco and Pizzigallo, where
m(PEA/PLD) improved quality of life on the basis of the SF-
12 assessment (a 12-item subset of the SF-36) for the physi-
cal (PCS-12) and mental (MCS-12) health summary scores,
while hormonal treatment improved only the PCS-12
summary score.33 Recently, the pilot study of Dell’Anna
and De Marzi investigated the efﬁcacy of a product based
on the combination of um-PEA+m(PEA/PLD) on the quality
of life in patients suffering from endometriosis with the
Endometriosis Health Proﬁle (EHP-30) questionnaire. The
results of this study showed a signiﬁcant improvement of the
“Emotional well-being” component over time,34 parallel to
an improvement of endometriosis pain symptoms, compar-
able to ours.
In our study, we also evaluated the effect of the treat-
ment on psychological well-being, using the SCL-90, a
scale that examines a wide range of psycho-pathological
symptoms such as somatization, obsessive-compulsive
syndrome, interpersonal sensitivity, depression, anxiety,
hostility, phobic anxiety, paranoid ideation, psychoticism,
and sleep disorders. The Positive Symptom Total of the
SCL-90 signiﬁcantly improved after 3 months of treatment
and this effect persisted after the end of treatment.
The ﬁnding that um-PEA and m(PEA/PLD) improve
women’s quality of life and psychological well-being
might be linked to the pain relief properties of the treat-
ment. However, recent medical research have demon-
strated the link between inﬂammatory diseases and mood
disorders.42,43 In particular, as regards endometriosis
patients, it was detected an immunological shift resulting
in the imbalance of pro-(IL-1β, IL-2, IFN-γ) and anti-
inﬂammatory (IL-4) cytokine production, correlated with
mood disorders such as depression and anxiety.44 Some
indications have shown that mast cells might act periph-
erally and centrally coordinate the inﬂammatory processes
in neuropsychiatric diseases supporting the hypothesis of
common pathways/mechanisms in the etiopathogenesis of
both chronic pelvic pain and depression.21,34,45,46
Therefore, targeting mast cells may represent a therapeutic
strategy to contrast the symptomatology of both diseases.
The main limitations of this open-label study include lack
of blindness and small patient sizes, which increases the
0
0,0
0,5
1,0
1,5
R
es
cu
e 
m
ed
ic
at
io
n 
(N
º t
ab
le
s)
2,0
2,5
10 30
*
Time (days)
60 90
(End of treatment)
120
Figure 2 Consumption of rescue drugs at baseline, after 10, 30, 60, 90 days and
after 30 days from the end of the treatment with um-PEA followed by m(PEA/PLD)
in patients affected from endometriosis. Consumption of rescue drugs (tablets)
showed a signiﬁcant reduction at the end of treatment compared to baseline. Data
values are expressed as means±SD *A p-value of <0.05 was considered signiﬁcant.
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difﬁculty in estimating the size effect of the treatment. Further,
a treatment period >3 months would allow one to better
appreciate the effectiveness and tolerability of the compound.
Despite these limitations, this open-label study provides
encouraging ﬁndings on the potential beneﬁts of um-PEA
and m(PEA/PLD) in patients affected by endometriosis.
Conclusion
Our research indicates the efﬁcacy and safety of um-PEA
and m(PEA/PLD) in the treatment of endometriosis symp-
tomatology. Their administration to patients who were not
taking any standard therapy provided a signiﬁcant
improvement in pain symptoms, in the quality of life and
in their psychological well-being. Given its effectiveness,
and absence of adverse events, um-PEA and m(PEA/PLD)
may be promising therapeutic strategies for the treatment
of endometriosis symptomatology, in particular for
patients unable to receive hormonal therapy or who desire
pregnancy. Future placebo-controlled, double-blind clini-
cal studies need to be conducted to evaluate the beneﬁts of
these treatments in larger populations.
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